Answers are grounded in this paper and cite their sources.
Case report reveals effectiveness of risankizumab for gastric outlet obstruction in isolated gastric Crohn's disease, suggesting potential therapeutic avenues.
Isolated gastric Crohn's Disease (IGCD) is a rare subset of Crohn's disease, poorly described in the literature. In this article, we present a 21-year-old man with gastric outlet obstruction secondary to IGCD. Management with Adalimumab and Upadacitinib failed, however he responded to Risankizumab. To our knowledge, this is the first case report documenting efficacy of Risankizumab in management of IGCD. In addition, we reviewed 13 published case reports describing IGCD. Ninety-two percent of cases were seen in women, typically presenting with nausea/vomiting and abdominal pain. Eighty-five percent of cases progressed to gastric outlet obstruction and tumor necrosis factor inhibitors were the first line advanced therapy.
No takes yet. Share an insight, caveat, or question.
Udine et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: